NWBO vs. ARDX

In the year-to-date period, NWBO achieves a -62.86% return, which is significantly lower than ARDX's -22.26% return. Over the past 10 years, NWBO has underperformed ARDX with an annualized return of -26.40%, while ARDX has yielded a comparatively higher -14.39% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Northwest Biotherapeutics, Inc. (NWBO) and Ardelyx, Inc. (ARDX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NWBO Sharpe Ratio is -0.99, which is lower than the ARDX Sharpe Ratio of -0.23. The chart below compares the historical Sharpe Ratios of NWBO and ARDX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither NWBO nor ARDX has paid dividends to shareholders.

The maximum NWBO drawdown since its inception was -99.99%, roughly equal to the maximum ARDX drawdown of -98.45%. Use the drawdown chart below to compare losses from any high point for NWBO and ARDX. For additional features, visit the drawdowns tool.

Northwest Biotherapeutics, Inc. (NWBO) has a higher volatility of 22.12% compared to Ardelyx, Inc. (ARDX) at 20.53%. This indicates that NWBO's price experiences larger fluctuations and is considered to be riskier than ARDX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Northwest Biotherapeutics, Inc. and Ardelyx, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.